Who are Ticagrelor- Delayed Administration's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ticagrelor + ASA, Blinded clopidogrel, Active Comparator: Rivaroxaban+Clopidogrel, Clopidogrel, Prasugrel, Ticagrelor, Chewing Ticagrelor LD, OAC + clopicogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-delayed-administration.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ticagrelor- Delayed Administration — Competitive Intelligence Brief

Ticagrelor- Delayed Administration (Ticagrelor- Delayed Administration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 platelet receptor antagonist. Area: Cardiovascular.

marketed P2Y12 platelet receptor antagonist P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor- Delayed Administration (Ticagrelor- Delayed Administration) — Massachusetts General Hospital. Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation to prevent thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ticagrelor- Delayed Administration TARGET	Ticagrelor- Delayed Administration	Massachusetts General Hospital	marketed	P2Y12 platelet receptor antagonist	P2Y12 receptor
ticagrelor + ASA	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Blinded clopidogrel	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
Active Comparator: Rivaroxaban+Clopidogrel	Active Comparator: Rivaroxaban+Clopidogrel	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Anticoagulant + Antiplatelet combination	Factor Xa; P2Y12 receptor
Clopidogrel, Prasugrel, Ticagrelor	Clopidogrel, Prasugrel, Ticagrelor	Centre hospitalier de l'Université de Montréal (CHUM)	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Chewing Ticagrelor LD	Chewing Ticagrelor LD	Sheba Medical Center	marketed	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 platelet receptor antagonist class)

Icahn School of Medicine at Mount Sinai · 2 drugs in this class
Collegium Medicum w Bydgoszczy · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor- Delayed Administration — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-delayed-administration. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab